Physical and chemical stability of drug nanoparticles.

By Libo Wu, Jian Zhang, Wiwik Watanabe. Advanced Drug Delivery Reviews, 2011

952 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Control of Polymeric Nanoparticle Size to Improve Therapeutic Delivery (2015, background): “Some of these materials are very sensitive to organic solvents leading to swelling, deposition of bioactive agents, or even aggregation of polymers (e.g. PLGA) on channel walls often resulting in channel clogging.”
Strategies to Address Low Drug Solubility in Discovery and Development (2013, methodology): “The term nanoparticle is frequently used to describe a range of nanosized materials, most commonly polymeric, liposomal, or solid lipid nanoparticles, but it also correctly describes nanoparticulate drug crystals and suspensions (Wu et al., 2011).”
Nanoparticles for Cancer Therapy: Current Progress and Challenges (2021, background): “Dry solid dosage forms are more stable than nano liquid products [181].”